查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1867047

動物模型市場：2025-2032年全球預測（按動物類型、模型類型、應用和最終用戶分類）

Animal Model Market by Animal Type, Model Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物模型市場將成長至 59.8 億美元，複合年成長率為 8.28%。

關鍵市場統計數據
基準年 2024 31.6億美元
預計年份：2025年 34.2億美元
預測年份 2032 59.8億美元
複合年成長率 (%) 8.28%

全面介紹科學進步、倫理要求和監管期望如何融合，從而重新定義臨床前動物模型策略。

現代動物模型領域正處於快速科學創新、嚴格的倫理要求和不斷發展的監管三者交匯的境地。臨床前研究人員和機構領導者必須應對日益複雜的環境，基因編輯技術的進步、飼養和模型表徵的改進以及不斷提高的可重複性標準共同影響決策。隨著研究機構、藥物研發人員和服務供應商不斷調整，對模型選擇、營運韌性和合規性方面的明確需求，對維持轉化研究的持續發展構成了核心挑戰。

在此背景下，相關人員日益強調檢驗的疾病模型和基因工程系統對於提高疾病相關性的重要性，同時也要應對外部壓力，改善動物使用方式並提升動物福利。這種動態變化要求我們對模型的能力和限制有深入的了解，並在適當情況下採用替代技術整合策略。因此，如何使科學目標與營運結構、供應商生態系統和監管要求相協調，已成為計劃成功和倫理管治的關鍵因素。

基因編輯技術、以福利為中心的管治和數位融合如何改變模型開發、檢驗方法和合作研究框架

一場變革浪潮正在重塑生物醫學研究中動物模型的發展、檢驗和應用方式。精準基因編輯技術的進步，特別是基於CRISPR的方法，正在加速建立高度精確的基因修飾模型，這些模型能夠更真實地模擬人類疾病的生物學過程。這正在改變模型選擇和實驗設計的標準。同時，表現型表徵和體內成像技術的改進增強了縱向研究的能力，並減少了達到可靠終點所需的動物數量，從而影響了資源分配和研究週期。

同時，倫理和監管環境對實驗實踐的影響日益增強。各機構和贊助商正在加強管治結構，以符合國際3R原則，從而加強對動物福利的監管，並要求對動物使用進行更充分的論證。為此，服務提供者和內部團隊正在加大對動物福利設施、豐富化計畫和員工培訓的投入，以滿足倫理要求和科學品質目標。同時，數位轉型和數據整合（包括實驗室資訊管理系統、標準化元資料實踐和機器學習驅動的分析）也在不斷發展，提高了實驗的可重複性，並加快了不同研究之間的比較。這些變化共同推動實驗模式向專業服務提供者的協作網路、集中式模型庫和能夠提供更可靠轉化研究結果的多學科團隊轉變。

2025年美國貿易政策演變對臨床前供應鏈、採購韌性與跨境合作準備的影響

美國預計在2025年將推出的政策干預措施和關稅調整，將為臨床前供應鏈和跨國合作帶來新的挑戰。影響特殊生物材料、客製化試劑和設備進出口的貿易措施，可能會影響採購前置作業時間和供應商選擇。因此，依賴國際供應商提供基因改造品系、種畜、專用耗材等產品的機構，可能需要重新評估其籌資策略，以減輕進口合規性審查加強和潛在成本重新分配對其營運的影響。

在實踐中，這些貿易趨勢正促使企業更加重視供應商多元化、關鍵產能回流以及在可行的情況下推動供應鏈區域化。各組織正在推動加強合約保障、完善庫存計劃以及對多家供應商進行認證，以確保研究的連續性並降低政策引發的中斷風險​​。此外，關稅對話正在促進行業相關人員和監管機構之間的討論，以協調材料轉移、檢疫和文件標準，並最大限度地減少行政摩擦。最後，對調查計畫而言，需要將貿易政策風險納入計劃時程和採購管治，以確保在跨境法規不斷變化的情況下，科學目標仍能有效實現。

可操作的細分分析揭示了物種選擇、模型建構、應用領域和最終用戶畫像如何產生不同的操作和科學優先事項。

細分分析揭示了動物物種、模型建構、應用領域和最終用戶如何塑造臨床前生態系統中多樣化的需求和策略重點。物種維度區分了非囓齒類動物和囓齒類動物，其中非囓齒類動物包括犬、非人靈長類動物和兔子等物種，而囓齒類動物則包括倉鼠、豚鼠、小鼠和大鼠。這種生物多樣性導致了法律規範、飼養要求和轉化應用的差異。因此，物種選擇決策越來越需要基於生理相關性和操作因素（例如繁殖週期、飼養空間和福利通訊協定）之間的平衡。

模型類型的分類進一步增加了複雜性：疾病模型、基因工程模型、藥理學模型和手術模型各自服務於不同的實驗目的。在基因工程方法中，CRISPR模型、基因敲入模型、基因敲除模型和基因轉殖模型等細分模型在技術架構和適用性方面存在差異，可用於標靶檢驗、機制研究和治療試驗。這些差異不僅影響實驗設計，也影響檢驗途徑和可重複性預期，因此各機構需要針對每類模型製定專門的標準作業規程（SOP）和表徵流程。

應用領域涵蓋ADME/PK研究、疾病研究、藥物發現與開發以及毒性評估，每個領域都有其獨特的可重複性要求、終點選擇和資料來源需求。例如，ADME和藥物動力學研究優先考慮受控的生理條件和精確的採樣，而疾病研究可能需要複雜的表現型分析和縱向結果測量。因此，對檢測平台、成像技術和生物分析能力的營運投資通常與組織的主要應用領域相符。

最終用戶涵蓋學術和研究機構、合約研究組織、醫院和診斷實驗室，以及製藥和生物技術公司，每個用戶群體都有不同的採購行為、監管責任和時間表。學術實驗室往往優先考慮探索性的靈活性和開放科學實踐，而合約研究組織則專注於滿足申辦者要求的可擴展、檢驗的工作流程。臨床實驗室和醫療系統將臨床前研究結果整合到轉化研究路徑和診斷開發中，而產業夥伴則需要強而有力的模型論證來支持監管申報。認知到這些基於細分市場的差異，有助於相關人員根據關鍵最終用戶群體的具體需求，調整模型選擇、供應商夥伴關係和管治框架。

區域分析重點在於美洲、歐洲、中東和非洲以及亞太地區對採購、合規和合作研究策略的影響。

區域趨勢正在影響關鍵地區動物模型來源、監管合規和合作研究策略的組織方式。美洲仍然是治療創新和合約研究活動的中心，密集的學術機構和商業贊助商網路推動了對特徵明確模型和專業服務的需求。這種能力的集中支持了強大的轉化項目，同時也加劇了對人才、基礎設施和實驗室空間的競爭，並促進了策略聯盟和資源共用模式的形成，從而最佳化了研究效率。

歐洲、中東和非洲地區擁有多元化的法規結構和倫理標準，這些都對模型開發和跨境交換產生影響。該地區許多司法管轄區都強調嚴格的動物福利標準和統一的監管，從而影響供應商認證實踐和研究設計要求。此外，區域合作聯盟和官民合作關係在匯集資源進行大規模臨床前舉措以及推廣標準化模型檢驗標準方面發揮重要作用。

亞太地區正迅速崛起為服務提供和模式創新領域的活力中心，這主要得益於基因編輯能力、育種基礎設施和合約研究能力的快速投資。各國監管方式的差異為區域專業化創造了機遇，而不斷成長的本土科學專長則促進了本土模式開發和轉化研究項目的發展。這些區域趨勢凸顯了針對各區域獨特風險和收益量身定做的籌資策略、合規藍圖和夥伴關係模式的重要性。

透過專業知識、數據整合和監管服務交付，推動競爭優勢的策略性企業行動和夥伴關係模式

動物模型生態系統中主要企業的行動體現了以專業化、垂直整合和協作服務交付為核心的策略重點。領先的供應商正投資於高保真基因操作技術和強大的育種項目，以提供差異化的模型產品組合。同時，許多服務公司正在拓展其分析和生物資訊服務，以在動物生產之外創造更多價值。這種將技術服務與先進數據解讀相結合的趨勢，旨在彌合轉化醫學鴻溝，並為申辦方提供來自臨床前計畫的更具可操作性的見解。

另一個重要的發展方向是透過夥伴關係與聯盟整合各項能力。這使得企業能夠結合營運優勢，例如動物飼養管理、再生醫學專業知識和生物成像技術，從而提供全面的服務。同時，一些供應商正在推行模組化外包模式，允許贊助公司在無需全面整合的情況下獲得特定能力。在這些策略中，對監管資訊、品管系統和動物福利認證的投資十分普遍，因為客戶越來越要求整個供應鏈具備可驗證的標準和可追溯性。這些公司層面的選擇將影響整個產業的競爭定位、客戶維繫以及不斷變化的服務水準預期。

為研究領導者提供切實可行的、優先排序的策略建議，以加速轉化成果的取得，同時提高模型可信度、加強供應鏈並改善福利合規性。

為了掌握當前機會並降低新興風險，產業領導者應積極整合科學研究投資、增強供應鏈韌性並管治。首先，引入先進的基因修飾模型技術（特別是CRISPR平台和全面的表現型分析流程）將有助於提高標靶檢驗，並降低下游轉化研究的不確定性。同時，各機構應制定模型表徵標準，並建立跨職能審查流程，以確保研究結果的可重複性和科學依據。

其次，供應鏈策略必須不斷演進，以降低貿易政策變化和供應中斷帶來的風險。這包括供應商關係多元化、對區域供應商合格，以及為關鍵任務材料建立緊急庫存。此外，投資本地養殖能力和建立區域夥伴關係可以縮短前置作業時間，並在商業不確定時期提供營運緩衝。第三，企業應透過整合強化監控技術、獨立審核和員工發展計劃，加強其福利和合規管治，以符合不斷變化的道德期望和監管要求。

最後，領導者應充分利用資料科學和數位平台來提高實驗效率。標準化元資料收集、實施可互通的實驗室系統以及部署機器學習進行終點預測，將提高實驗的可重複性，並支援更快的決策週期。這些措施將增強科學信譽、營運穩定性以及相關人員的信任，為各機構在應對政策和倫理要求的同時保持轉化研究動力奠定基礎。

結合專家訪談、系統性文獻綜述和迭代檢驗的穩健的多源調查方法，確保了研究結果的有效性和可操作性。

本分析的調查方法採用分層式策略，將初步的質性見解與結構化的二次檢驗結合。初步資訊包括諮詢臨床前研究、獸醫學和監管事務領域的專家，以捕捉細微的營運實際情況和新興的科學趨勢。此外，也透過系統性地回顧同儕審查文獻、技術指導文件和公認標準，來闡釋技術進步和動物福利實踐的背景。

透過資料三角驗證，將專家意見與已發布的技術調查方法透明公開，清楚記錄了納入標準、模型分類定義以及技術論點的依據。整個過程中都強調了倫理考量，並在專家訪談中尊重了資料隱私和職業保密。這種多來源、迭代式的方法有助於對行業趨勢進行合理的解讀，並為尋求營運指導和科學依據的決策者提供量身定做的見解。

總之，強調整合科學嚴謹性、倫理管治和供應鏈韌性的整體觀點將有助於轉化研究的持續成功。

總之，動物模型領域正經歷專業化程度提高、倫理課責加強和運作模式調整的階段。基因編輯和表現型表徵等科學進步正在提升模型的轉化準確性，而監管機構和相關人員也不斷提高對動物福利和可重複性的要求。這些並行發展的趨勢要求各機構謹慎選擇模型，增強供應鏈的靈活性，並投資於能夠支援可靠轉化結果的資料管治基礎設施。

未來的成功取決於能否將技術能力、負責任的管理和切實可行的營運規劃融會貫通。那些積極將科研議程與強力的採購慣例實踐和透明的福利管治相結合的機構，將更有能力提供高品質的臨床前證據，並能靈活應對政策和市場的變化。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • CRISPR/Cas9基因編輯動物模型在罕見疾病研究和藥物研發的快速應用
  • 擴大採用人源化小鼠模型來評估腫瘤免疫療法的療效和安全性
  • 將人工智慧驅動的影像分析和行為追蹤技術整合到臨床前動物模型表現型分析工作流程中
  • 加大對大型動物模型（例如豬和非人靈長類動物）在異種移植研究中的投入
  • 晶片器官和3D生物列印組織平台作為傳統動物試驗的替代方案的出現
  • 監管壓力推動體外和計算模型的發展，以減少對動物測試的依賴

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：以動物類型分類的動物模型市場

  • 不囓齒類動物
    • 狗
    • 非人靈長類動物
    • 兔子
  • 囓齒動物
    • 倉鼠和天竺鼠
    • 老鼠
    • 鼠

第9章：依模型類型分類的動物模型市場

  • 疾病模型
  • 基因工程模型
    • CRISPR模型
    • 敲入式模型
    • 淘汰賽模特兒
    • 基因改造模型
  • 藥理學模型
  • 手術模型

第10章：按應用分類的動物模型市場

  • ADME和藥物動力學研究
  • 疾病監測
  • 藥物發現與開發
  • 毒性評價

第11章 按最終用戶分類的動物模型市場

  • 學術和研究機構
  • CRO（合約研究組織）
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

第12章：各地區動物模型市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：依組別分類的動物模型市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國動物模型市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Charles River Laboratories International, Inc.
    • Envigo RMS, Inc.
    • The Jackson Laboratory
    • Taconic Biosciences, Inc.
    • Laboratory Corporation of America Holdings
    • Wuxi AppTec Co., Ltd.
    • Evotec AG
    • Crown Bioscience, Inc.
    • Janvier Labs SAS
    • GemPharmatech Co., Ltd.
Product Code: MRR-5D693B46BD18

The Animal Model Market is projected to grow by USD 5.98 billion at a CAGR of 8.28% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.16 billion
Estimated Year [2025] USD 3.42 billion
Forecast Year [2032] USD 5.98 billion
CAGR (%) 8.28%

A comprehensive introduction outlining how scientific progress, ethical imperatives, and regulatory expectations converge to redefine preclinical animal model strategies

The contemporary animal model landscape sits at the intersection of rapid scientific innovation, stringent ethical expectations, and evolving regulatory oversight. Preclinical investigators and organizational leaders must navigate an increasingly complex environment where advances in gene editing, improvements in husbandry and model characterization, and heightened reproducibility standards collectively influence decision-making. As research institutions, pharmaceutical developers, and service providers adapt, the demand for clarity around model selection, operational resilience, and compliance has become central to sustaining translational pipelines.

Across this environment, stakeholders are placing greater emphasis on validated disease models and genetically engineered systems to increase translational relevance while simultaneously responding to external pressures to refine animal use and enhance welfare. This dynamic requires a nuanced understanding of model capabilities and limitations, as well as strategies for integrating alternative technologies where appropriate. Consequently, the ability to align scientific objectives with operational structures, vendor ecosystems, and regulatory expectations is now a critical determinant of project success and ethical stewardship.

How gene editing, welfare-driven governance, and digital integration are jointly transforming model development, validation practices, and collaborative research frameworks

Significant transformative shifts are reshaping how animal models are developed, validated, and deployed across biomedical research. Advances in precision gene editing, particularly CRISPR-based approaches, are accelerating the creation of highly specific genetically engineered models that better recapitulate human disease biology, thereby changing the calculus for model selection and experimental design. At the same time, improvements in phenotype characterization and in vivo imaging are enhancing longitudinal study capabilities and reducing the number of animals required for robust endpoints, which in turn affects resource allocation and study timelines.

Concurrently, ethical and regulatory landscapes are exerting stronger influence over experimental practice. Institutions and sponsors are strengthening governance frameworks to align with international 3Rs principles, resulting in more rigorous welfare monitoring and justification for animal use. In response, service providers and internal teams are increasingly investing in welfare-positive housing, enrichment programs, and staff training to meet both ethical expectations and scientific quality goals. In parallel, digital transformation and data integration-encompassing laboratory information management systems, standardized metadata practices, and machine learning-enabled analytics-are improving reproducibility and enabling more rapid cross-study comparisons. These combined shifts are driving a migration toward collaborative networks of specialized providers, centralized model repositories, and multidisciplinary teams that can deliver higher-confidence translational outputs.

Implications of evolving US trade measures for preclinical supply chains, procurement resilience, and cross-border collaboration preparedness in 2025

Policy interventions and tariff adjustments in the United States projected for 2025 are introducing new considerations for preclinical supply chains and cross-border collaborations. Trade measures that affect the import and export of specialized biological materials, custom reagents, and equipment can influence procurement lead times and vendor selection decisions. As a result, organizations that rely on international suppliers for genetically engineered lines, breeding stock, or specialized consumables may need to reassess sourcing strategies to mitigate the operational impact of elevated import compliance scrutiny and potential cost reallocation.

In practical terms, these trade dynamics are prompting greater attention to supplier diversification, onshoring of critical production capabilities, and regionalization of supply chains where feasible. Organizations are emphasizing contractual protections, enhanced inventory planning, and multi-supplier qualification to ensure continuity of studies and reduce exposure to policy-driven disruptions. Moreover, the tariffs dialogue is catalyzing conversations between industry stakeholders and regulatory authorities about harmonizing standards for material transfer, quarantine, and documentation to minimize administrative friction. Ultimately, the implication for research programs is a need to integrate trade policy risk into project timelines and procurement governance so that scientific objectives remain resilient in the face of shifting cross-border rules.

Actionable segmentation intelligence revealing how species selection, model construction, application focus, and end-user profiles create differentiated operational and scientific priorities

Segmentation insights reveal how distinct animal types, model constructs, application areas, and end users shape heterogeneous demands and strategic priorities across the preclinical ecosystem. The animal type dimension differentiates Nonrodents and Rodents, where Nonrodents encompass species such as Dogs, Nonhuman Primates, and Rabbits, and Rodents include Hamsters & Guinea Pigs, Mice, and Rats; this biological diversity drives variation in regulatory oversight, housing requirements, and translational applicability. Therefore, decisions about species selection are increasingly informed by the balance between physiological relevance and operational considerations such as breeding cycles, housing footprint, and welfare protocols.

Model type granularity further layers complexity: Disease Models, Genetically Engineered Models, Pharmacological Models, and Surgical Models each serve distinct experimental purposes. Within genetically engineered approaches, subdivisions such as CRISPR Models, Knock-In Models, Knockout Models, and Transgenic Models differ in their technical construction and applicability for target validation, mechanistic studies, and therapeutic testing. These differences influence not only experimental design but also validation pathways and reproducibility expectations, leading organizations to develop tailored standard operating procedures and characterization pipelines for each model class.

Applications span ADME & PK Studies, Disease Research, Drug Discovery & Development, and Toxicology Assessment, and each application imposes unique fidelity requirements, endpoint selection, and data provenance needs. For instance, ADME and pharmacokinetic investigations prioritize controlled physiology and precise sampling, whereas disease research may require complex phenotyping and longitudinal outcome measures. As a result, operational investments in assay platforms, imaging modalities, and bioanalytical capacity are frequently aligned to the dominant application portfolio of an organization.

End users range from Academic & Research Institutes to Contract Research Organizations, Hospitals & Diagnostic Laboratories, and Pharmaceutical & Biotechnology Companies, each bringing different procurement behaviors, regulatory responsibilities, and timelines. Academic labs often prioritize exploratory flexibility and open science practices, while contract research organizations focus on scalable, validated workflows that meet sponsor requirements. Clinical laboratories and health systems integrate preclinical insights into translational pathways and diagnostic development, and industry partners require robust model justification to support regulatory submissions. Recognizing these segmentation-driven differences enables stakeholders to align model selection, vendor partnerships, and governance frameworks with the specific needs of their primary end-user constituencies.

Regional analysis highlighting how the Americas, Europe Middle East & Africa, and Asia-Pacific each influence sourcing, compliance, and collaborative research strategies

Regional dynamics are shaping how organizations approach animal model sourcing, regulatory compliance, and collaboration strategies across key geographies. The Americas continue to be a hub for therapeutic innovation and contract research activity, with dense networks of academic institutions and commercial sponsors that drive demand for characterized models and specialized services. This concentration of capability supports robust translational programs, yet it also elevates competition for talent, infrastructure, and laboratory space, encouraging strategic alliances and shared-resource models to optimize throughput.

Europe, Middle East & Africa present a mosaic of regulatory frameworks and ethical norms that influence model development and cross-border exchanges. Many jurisdictions in this region emphasize stringent welfare standards and harmonized oversight, which in turn shape vendor certification practices and study design expectations. Additionally, collaborative pan-regional consortia and public-private partnerships play a notable role in pooling resources for large-scale preclinical initiatives and in advancing standardized model validation criteria.

Asia-Pacific has emerged as a dynamic region for both service provision and model innovation, with rapid investment in gene editing capacity, breeding infrastructure, and contract research capabilities. Diverse regulatory approaches across countries create opportunities for regional specialization, while increasing local scientific expertise is fostering indigenous model development and translational research programs. Together, these regional patterns highlight the importance of tailoring sourcing strategies, compliance roadmaps, and partnership approaches to the specific risks and advantages present within each geography.

Strategic company behaviors and partnership models that drive competitive differentiation through specialization, data integration, and regulatory-aligned service offerings

Key company behaviors in the animal model ecosystem reflect strategic prioritization around specialization, vertical integration, and collaborative service delivery. Leading providers are investing in high-fidelity genetically engineered capabilities and robust breeding programs to offer differentiated model portfolios, while many service firms are expanding their analytics and bioinformatics layers to add value beyond animal production. This trend toward bundling technical services with deeper data interpretation aims to reduce translational gaps and to provide sponsors with more actionable insights from preclinical programs.

Another notable direction is the consolidation of capabilities through partnerships and alliances, enabling organizations to combine operational strengths-such as vivarium management, regenerative medicine expertise, or in vivo imaging-into comprehensive service offerings. At the same time, some providers are pursuing modular, outsourced arrangements that allow sponsors to access specific competencies without committing to full-scale integration. Across these strategies, investment in regulatory intelligence, quality management systems, and welfare accreditation is common, as customers increasingly demand demonstrable standards and traceability across the supply chain. These company-level choices influence competitive positioning, client retention, and the evolution of service-level expectations across the sector.

Practical and prioritized strategic recommendations for research leaders to enhance model fidelity, fortify supply chains, and elevate welfare compliance while accelerating translational outcomes

Industry leaders should adopt a proactive mix of scientific investment, supply chain resilience, and governance enhancements to capitalize on current opportunities and mitigate emerging risks. First, embedding advanced genetically engineered model capabilities-especially CRISPR-enabled platforms and comprehensive phenotyping workflows-will improve target validation and reduce downstream translational uncertainty. Complementing this, organizations should formalize model characterization standards and establish cross-functional review processes that ensure reproducibility and defendable scientific rationale.

Second, supply chain strategies must evolve to reduce exposure to trade policy shifts and supply interruptions. This involves diversifying vendor relationships, qualifying regional suppliers, and developing contingency inventories for mission-critical materials. In addition, investing in localized breeding capacity or regional partnerships can shorten lead times and provide operational buffers during periods of commerce volatility. Third, companies should elevate welfare and compliance governance by integrating enhanced monitoring technologies, independent audits, and staff competency programs that align with evolving ethical expectations and regulatory scrutiny.

Finally, leaders should leverage data science and digital platforms to achieve higher experimental efficiency. Standardizing metadata capture, adopting interoperable laboratory systems, and deploying machine learning for endpoint prediction will increase reproducibility and support faster decision cycles. Combined, these actions enhance scientific credibility, operational stability, and stakeholder trust, positioning organizations to sustain translational momentum while remaining responsive to policy and ethical imperatives.

Robust multi-source research methodology combining expert consultations, systematic literature synthesis, and iterative validation to ensure defensible and actionable insights

The research methodology underpinning this analysis leverages a layered approach that synthesizes primary qualitative insights with structured secondary validation. Primary inputs include consultations with subject-matter experts across preclinical research, veterinary sciences, and regulatory affairs to capture nuanced operational realities and emerging scientific trends. These interviews were supplemented by a systematic review of peer-reviewed literature, technical guidance documents, and recognized standards to contextualize technological advances and welfare practices.

Data triangulation ensured robustness by cross-referencing expert perspectives with publicly available technical reports and documented policy changes. Wherever applicable, methodological transparency was maintained through clear documentation of inclusion criteria, definitions for model classes, and the provenance of technical assertions. Ethical considerations guided the process throughout, with respect for data privacy and professional confidentiality in all expert engagements. This multi-source, iterative approach supports a defensible interpretation of sector dynamics and yields insights tailored to decision-makers requiring both operational guidance and scientific credibility.

A conclusive synthesis emphasizing the need to integrate scientific precision, ethical governance, and supply chain resilience to sustain translational success

In conclusion, the animal model landscape is entering a period of refined specialization, heightened ethical accountability, and operational recalibration. Scientific advances-especially in gene editing and phenotype characterization-are improving the translational precision of models, while at the same time regulators and stakeholders are raising the bar for welfare and reproducibility. These concurrent forces require organizations to be deliberate in model selection, to strengthen supply chain agility, and to invest in data and governance infrastructures that support reliable translational outcomes.

Looking forward, success will depend on the ability to integrate technological capabilities with responsible stewardship and pragmatic operational planning. Organizations that proactively align their scientific agendas with resilient procurement practices and transparent welfare governance will be better positioned to deliver high-quality preclinical evidence and to respond to policy or market shifts with agility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of CRISPR/Cas9 gene-edited animal models for rare disease research and drug discovery
  • 5.2. Growing preference for humanized mouse models in oncology immunotherapy efficacy and safety evaluation
  • 5.3. Integration of AI-powered image analysis and behavioral tracking in preclinical animal model phenotyping workflows
  • 5.4. Increasing investment in large animal models such as pigs and non-human primates for xenotransplantation studies
  • 5.5. Emergence of organ-on-a-chip and 3D bioprinted tissue platforms as alternatives to traditional animal testing
  • 5.6. Regulatory pressure driving development of in vitro and computational models to reduce reliance on animal experiments

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Model Market, by Animal Type

  • 8.1. Nonrodents
    • 8.1.1. Dogs
    • 8.1.2. Nonhuman Primates
    • 8.1.3. Rabbits
  • 8.2. Rodents
    • 8.2.1. Hamsters & Guinea Pigs
    • 8.2.2. Mice
    • 8.2.3. Rats

9. Animal Model Market, by Model Type

  • 9.1. Disease Models
  • 9.2. Genetically Engineered Models
    • 9.2.1. CRISPR Models
    • 9.2.2. Knock-In Models
    • 9.2.3. Knockout Models
    • 9.2.4. Transgenic Models
  • 9.3. Pharmacological Models
  • 9.4. Surgical Models

10. Animal Model Market, by Application

  • 10.1. ADME & PK Studies
  • 10.2. Disease Research
  • 10.3. Drug Discovery & Development
  • 10.4. Toxicology Assessment

11. Animal Model Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Diagnostic Laboratories
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Animal Model Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Model Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Model Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Charles River Laboratories International, Inc.
    • 15.3.2. Envigo RMS, Inc.
    • 15.3.3. The Jackson Laboratory
    • 15.3.4. Taconic Biosciences, Inc.
    • 15.3.5. Laboratory Corporation of America Holdings
    • 15.3.6. Wuxi AppTec Co., Ltd.
    • 15.3.7. Evotec AG
    • 15.3.8. Crown Bioscience, Inc.
    • 15.3.9. Janvier Labs SAS
    • 15.3.10. GemPharmatech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANIMAL MODEL MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANIMAL MODEL MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL MODEL MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL MODEL MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONRODENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL MODEL MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL MODEL MARKET SIZE, BY NONHUMAN PRIMATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL MODEL MARKET SIZE, BY RABBITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL MODEL MARKET SIZE, BY RODENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL MODEL MARKET SIZE, BY HAMSTERS & GUINEA PIGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL MODEL MARKET SIZE, BY MICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL MODEL MARKET SIZE, BY RATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL MODEL MARKET SIZE, BY CRISPR MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCK-IN MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACOLOGICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL MODEL MARKET SIZE, BY SURGICAL MODELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL MODEL MARKET SIZE, BY ADME & PK STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL MODEL MARKET SIZE, BY DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL MODEL MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL MODEL MARKET SIZE, BY TOXICOLOGY ASSESSMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL MODEL MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL ANIMAL MODEL MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. GCC ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. GCC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. GCC ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. GCC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 316. GCC ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 317. GCC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 318. GCC ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 319. GCC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. GCC ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. GCC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 322. GCC ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 323. GCC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 324. GCC ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 325. GCC ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. GCC ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY MODEL TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MODELS, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPEAN UNION ANIMAL MODEL MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. BRICS ANIMAL MODEL MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. BRICS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. BRICS ANIMAL MODEL MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. BRICS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2018-2024 (USD MILLION)
  • TABLE 348. BRICS ANIMAL MODEL MARKET SIZE, BY NONRODENTS, 2025-2032 (USD MILLION)
  • TABLE 349. BRICS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2018-2024 (USD MILLION)
  • TABLE 350. BRICS ANIMAL MODEL MARKET SIZE, BY RODENTS, 2025-2032 (USD MILLION)
  • TABLE 351. BRICS ANIMAL MOD